Amgen's Broad Portfolio Strength and Wide Moat Should Protect Profits Despite Upcoming Biosimilars
Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...
Medical Devices Firm Lensar Surges Ahead On Robotic Technology
LENSAR, Inc.'s ALLY Robotic Cataract Laser System has driven significant revenue and earnings growth. Read why LNSR stock is ...